0000947871-21-000520.txt : 20210513
0000947871-21-000520.hdr.sgml : 20210513
20210513183433
ACCESSION NUMBER: 0000947871-21-000520
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210511
FILED AS OF DATE: 20210513
DATE AS OF CHANGE: 20210513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OrbiMed Israel GP Ltd.
CENTRAL INDEX KEY: 0001569590
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37797
FILM NUMBER: 21921221
BUSINESS ADDRESS:
STREET 1: 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR
CITY: HERZLIYA
STATE: L3
ZIP: 46766
BUSINESS PHONE: 212-739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022-4629
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OrbiMed Israel BioFund GP Limited Partnership
CENTRAL INDEX KEY: 0001569821
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37797
FILM NUMBER: 21921220
BUSINESS ADDRESS:
STREET 1: 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR
CITY: HERZLIYA
STATE: L3
ZIP: 46766
BUSINESS PHONE: 212-739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 1022-4629
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 9 METERS BIOPHARMA, INC.
CENTRAL INDEX KEY: 0001551986
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273948465
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: 919-275-1933
MAIL ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20180201
FORMER COMPANY:
FORMER CONFORMED NAME: Monster Digital, Inc.
DATE OF NAME CHANGE: 20150930
FORMER COMPANY:
FORMER CONFORMED NAME: Tandon Digital, Inc.
DATE OF NAME CHANGE: 20120611
4
1
ownership.xml
X0306
4
2021-05-11
0
0001551986
9 METERS BIOPHARMA, INC.
NMTR
0001569590
OrbiMed Israel GP Ltd.
C/O 9 METERS BIOPHARMA, INC.
8480 HONEYCUTT RD, STE 120
RALEIGH
NC
27615
0
0
1
0
0001569821
OrbiMed Israel BioFund GP Limited Partnership
89 MEDINAT HAYEHUDIM ST., BUILDING E
HERZLIYA
L3
4614001
ISRAEL
0
0
1
0
Common Stock
2021-05-11
4
X
0
12500
0.7
A
25729255
I
See Footnotes
Common Stock
2021-05-11
4
X
0
19444
0.6216
A
25748699
I
See Footnotes (1)(2
Stock Option (right to buy)
0.7
2021-05-11
4
X
0
12500
0
A
2030-04-30
Common Stock
12500
37500
I
See Footnotes
Stock Option (right to buy)
0.6216
2021-05-11
4
X
0
19444
0
A
2030-07-06
Common Stock
19444
80556
I
See Footnotes
These shares of the Issuer's common stock are held of record by Nissim Darvish ("Darvish"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OrbiMed Israel Partners Limited Partnership ("OIP"), and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
This option was granted to Darvish on April 30, 2020 and vests in 36 monthly installments beginning April 30, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
This option was granted to Darvish on July 6, 2020 and vests in 36 monthly installments beginning July 6, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Israel GP Ltd.
2021-05-13
/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Israel BioFund GP Limited
2021-05-13